VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Sohal on Perioperative mFOLFIRINOX in Pancreatic Adenocarcinoma

Davendra Sohal, MD, MPH
Published: Thursday, Jun 22, 2017



Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.

SWOG S1505 is one of the first cooperative group studies exploring this treatment in pancreatic cancer, Sohal explains. It is a shift from the standard of care for these patients, which is surgery followed by adjuvant chemotherapy with or without radiation therapy. However, research now shows that pancreatic cancer is a systemic disease and it should be targeted with aggressive systemic chemotherapy regimens upfront.

This is what this study is testing, Sohal adds—the efficacy, safety, and feasibility of this approach.


Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.

SWOG S1505 is one of the first cooperative group studies exploring this treatment in pancreatic cancer, Sohal explains. It is a shift from the standard of care for these patients, which is surgery followed by adjuvant chemotherapy with or without radiation therapy. However, research now shows that pancreatic cancer is a systemic disease and it should be targeted with aggressive systemic chemotherapy regimens upfront.

This is what this study is testing, Sohal adds—the efficacy, safety, and feasibility of this approach.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x